Laboratory:Akiruno
- TOP
- haematological test
- coagulation- and fibrinolysis-related test
Laboratory:Akiruno
○coagulation- and fibrinolysis-related test
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
Activated partial thromboplastin time (APTT)
|
Plasma 0.5 |
PC2 ↓ A00 |
|
2-4 |
Clotting time measurement method Clotting time method |
24.3-36.0 (seconds) | |
|
Plasma 0.5 |
PC2 ↓ A00 |
|
2-4 |
Clotting time measurement method Clotting time method |
Seconds:10.5-13.5 (seconds) %:70-130 (%) Ratio:0.85-1.15 |
|
Fibrinogen (FIB)
|
Plasma 0.5 |
PC2 ↓ A00 |
|
2-4 |
Clotting time measurement method Clotting time method |
150-400(mg/dL) | |
Soluble fibrin monomer complex (SFMC)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
LPIA LPIA (Latex photometric immunoassay) |
Less than 7 (μg/mL) negative | |
Fibrin monomer complex quantitation
|
Plasma 0.5 |
PC2 ↓ A00 |
(21 days) |
2-4 | Latex immunoturbidimetry | 6.1 or less (μg/mL) | |
Quantitative FDP
|
Plasma 0.3 |
PC2 ↓ A00 |
(21 days) |
2-4 | Latex immunoturbidimetry | 4 or less (μg/mL) | |
Quantitative FDP
|
Partial urine
0.5 |
U90 ↓ A00 |
(21 days) |
2-6 |
LPIA LPIA (Latex photometric immunoassay) |
100 or less (ng/mL) | |
D-dimer
|
Plasma 0.5 |
PC2 ↓ A00 |
(21 days) |
2-4 | Latex immunoturbidimetry | 1.0 or less (μg/mL) | |
Prothrombin fragment F1+2
|
Plasma 0.3 |
PC2 ↓ A00 |
(21 days) |
2-5 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) A method in which after reacting an antigen with a solid-phase antibody, an enzyme-labeled antibody is reacted with the antigen in a secondary reaction, and the enzyme activity is measured by adding a chromogenic substrate. |
69-229(pmol/L) | |
Antithrombin III (AT-III)
|
Plasma 0.5 |
PC2 ↓ A00 |
(1 month) |
2-4 |
Chromogenic synthetic substrate method Chromogenic substrate method |
79-121(%) | |
Thrombin-antithrombin III complex (TAT)
|
Plasma 0.5 |
PC2 ↓ A00 |
(21 days) |
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
3.0 or less (ng/mL) | |
Plasminogen
|
Plasma 0.5 |
PC2 ↓ A00 |
|
2-4 |
Chromogenic synthetic substrate method Chromogenic substrate method |
75-125(%) | |
Antiplasmin (α2 plasmin inhibitor)
|
Plasma 0.5 |
PC2 ↓ A00 |
(1 month) |
2-4 |
Chromogenic synthetic substrate method Chromogenic substrate method |
85-115(%) | |
α2Plasmin Inviter/Plasmin Complex (PIC test)
|
Plasma 0.2 |
PC2 ↓ A00 |
(21 days) |
2-4 |
LPIA LPIA (Latex photometric immunoassay) |
0.8 or less (μg/mL) | |
Total PAI-1 (tPA・PAI-1 complex)
|
Plasma 0.5 |
PC2 ↓ A00 |
(21 days) |
2-5 |
LPIA LPIA (Latex photometric immunoassay) |
50 or less (ng/mL) | |
Coagulation factor activity test Factor VIII (F8) 〔synthetic substrate method〕
|
Plasma 0.3 |
PC2 ↓ A00 |
(7 days) |
2-6 |
Synthetic substrate method Chromogenic substrate method |
60-140(%) | |
Coagulation factor activity test Factor IX (F9) 〔synthetic substrate method〕
|
Plasma 0.3 |
PC2 ↓ A00 |
(28 days) |
2-6 |
Synthetic substrate method Chromogenic substrate method |
60-140(%) | |
Coagulation factor activity test Factor II (F2)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
75-135(%) | |
Coagulation factor activity test Factor V (F5)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
70-135(%) | |
Coagulation factor activity test Factor VII (F7)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
75-140(%) | |
Coagulation factor activity test Factor VIII (F8)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
60-150(%) | |
Coagulation factor activity test Factor IX (F9)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
70-130(%) | |
Coagulation factor activity test Factor X (F10)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
70-130(%) | |
Coagulation factor activity test Factor XI (F11)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
75-145(%) | |
Coagulation factor activity test Factor XII (F12)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Clotting time method Clotting time method |
50-150(%) | |
Coagulation factor activity test Factor ⅩⅢ (F13)
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
Synthetic substrate method Chromogenic substrate method |
70-140(%) | |
Von Willbrand factor antigen quantitative
|
Plasma 0.2 |
PC2 ↓ A00 |
(21 days) |
2-4 |
latex agglutination reaction LA (Latex agglutination) |
50-155(%) | |
Coagulation inhibitor identification Factor VIII
|
Plasma 1.0 |
PC5 ↓ A00 |
|
2-4 | Bethesda Act | Not detected (Bethesda U/mL) | |
Coagulation inhibitor identification Factor IX
|
Plasma 1.0 |
PC5 ↓ A00 |
(21 days) |
2-4 | Bethesda Act | Not detected (Bethesda U/mL) | |
Von-Wilbrand factor activity (Ristocetin cofactor)
|
Plasma 0.5 |
PC2 ↓ A00 |
(20 days) |
2-4 | Fixed platelet aggregation method | 60-170(%) | |
Von-Wilbrand factor multimer analysis
|
Plasma 0.4 |
PC2 ↓ A00 |
(1 month) |
7-14 |
SDS agarose gel electrophoresis method Electrophoresis method |
NORMAL pattern | |
ADAMTS13 activity
|
Plasma 0.3 |
PC2 ↓ A00 |
(28 days) |
2-5 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) A method in which after reacting an antigen with a solid-phase antibody, an enzyme-labeled antibody is reacted with the antigen in a secondary reaction, and the enzyme activity is measured by adding a chromogenic substrate. |
0.10 or more (IU/mL) 10 or more (%) |
|
ADAMTS13 inhibitor
|
Plasma 0.6 |
PC2 ↓ A00 |
(28 days) |
2-5 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) A method in which after reacting an antigen with a solid-phase antibody, an enzyme-labeled antibody is reacted with the antigen in a secondary reaction, and the enzyme activity is measured by adding a chromogenic substrate. |
Less than 0.5 (BU/mL) Negative |
|
β-thromboglobulin (β-TG)
|
Platelet-poor plasma 0.3 |
PBT ↓ A00 |
(1 month) |
2-9 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
50 or less (ng/mL) | |
Platelet factor-4 (PF-4)
|
Platelet-poor plasma 0.3 |
PBT ↓ A00 |
(1 month) |
2-9 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
20 or less (ng/mL) | |
Protein C (antigen level)
|
Plasma 0.3 |
PC2 ↓ A00 |
|
2-5 |
LPIA LPIA (Latex photometric immunoassay) |
70-150(%) | |
Protein C activity
|
Plasma 0.4 |
PC2 ↓ A00 |
|
2-4 |
Clotting time method Clotting time method |
64-146(%) | |
Protein S (antigen level)
|
Plasma 0.2 |
PC2 ↓ A00 |
(21 days) |
2-4 |
latex agglutination reaction LA (Latex agglutination) |
M 73-137 F 59-143 (%) |
|
Protein S activity
|
Plasma 0.4 |
PC2 ↓ A00 |
|
2-4 |
Clotting time method Clotting time method |
M 67-164 F 56-126 (%) |
|
Protein S (free antigen level)
|
Plasma 0.2 |
PC2 ↓ A00 |
(21 days) |
2-4 |
latex agglutination reaction LA (Latex agglutination) |
M 50-131 F 49-133 (%) |
|
Thrombomodulin
|
Serum
0.4 |
S09 ↓ A00 |
(21 days) |
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
12.1-24.9(U/mL) | |
Thrombomodulin
|
Plasma 0.4 |
PC2 ↓ A00 |
(21 days) |
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
8.7-22.7(U/mL) | |
|
Plasma
0.5 |
PC2 ↓ A00 |
|
Enzyme immunoassay(EIA) EIA (Enzyme Immunoassay Assay) |
3.0 or less (ng/mL) | ||
|
Plasma 0.5 |
PC2 ↓ A00 |
|
2-4 |
Clotting time measurement method Clotting time method |
70-130(%) | |
|
Plasma 0.5 |
PC2 ↓ A00 |
|
2-4 |
Clotting time measurement method Clotting time method |
70 or more (%) |